左乙拉西坦添加疗法治疗青年难治性部分性癫痫的疗效及其对患者认知功能和生活质量的影响

目的 观察左乙拉西坦添加疗法治疗青年难治性部分性癫痫的临床疗效,并探析其对患者认知功能和生活质量的影响.方法 前瞻性选取2012年1月至2015年1月神经内科门诊收治的120例青年难治性部分性癫痫患者,采用随机数字表法将其分为两组各60例,对照组患者给予常规治疗,观察组在此基础上给予左乙拉西坦治疗,观察两组患者的治疗效果、不良反应以及认知功能和生活质量评分情况.结果 观察组患者用药3个月、6个月后的治疗总有效率分别为71.67%(43/60)、81.67%(49/60),均明显高于对照组的35.00%(21/60)、65.00%(39/60),不良反应发生率为13.33%(8/60),明显低于对照组的33.33%(20/60),差异均有统计学意义(P<0.05);观察组和对照组治疗6个月末认知功能MoCA评分分别为(29.58±1.06)分、(29.45±0.68)分,均较治疗前的(28.38±1.06)分、(28.52±1.05)分明显增高,差异均有统计学意义(P<0.05),但组间比较差异无统计学意义(P>0.05);观察组和对照组治疗3个月、6个月末QOLIE-31评分较治疗前均明显增高,差异有统计学意义(P<0.05),且观察组患者各时刻评分均明显高于对照组,差异均有统计学意义(P<0.05).结论 左乙拉西坦添加治疗青年难治性部分性癫痫疗效确切,安全性高,可明显改善患者的认知功能,提高生活质量,可作为临床首选药物治疗方案.

Efficacy of adjunctive levetiracetam in young patients with refractory partial epilepsy and its effects on cognitive function and quality of life

Objective To investigate the efficacy of adjunctive levetiracetam in treatment of refractory partial epilepsy in young patients and its effects on cognitive function and quality of life. Methods A total of 120 young pa-tients with refractory partial epilepsy, who were treated in Department of Neurology of the Second People's Hospital of Nanchong City from January 2012 to January 2015, were selected as research objects, and all of these patients were ran-domly divided into control group with conventional treatment and treatment group with adjunctive levetiracetam, with 60 patients in each group. Treatment effect, adverse reactions and cognitive function and quality of life score of the two groups were evaluated. Results The total efficiency after 3 and 6 months 71.67%(43/60), 81.67%(49/60), respective-ly] in treatment group was significantly higher than those 35.00% (21/60), 65.00% (39/60), respectively]in the con-trol group (P<005). The incidence of adverse reaction in treatment group (13.33%, 8/60) was significantly lower than the control group (33.33%, 20/60, P<005). MOCA cognitive function scores of treatment group and control group af-ter 6 months (29.58 ± 1.06), (29.45 ± 0.68), respectively] were significantly higher (P<0.05) than before treatment (28.38 ± 1.06), (28.52 ± 1.05), respectively], but there was no statistical significance difference between two groups (P>0.05). QOLIE-31 score of treatment group and control group after 3 and 6 months was significantly higher than before treatment (P<0.05). Moreover, the QOLIE-31 scores of treatment group were significantly higher than the control group (P<0.05). Conclusion Adjunctive levetiracetam can significantly improve cognitive function and quality of life of young patients with refractory partial epilepsy with high safety and curative effect, which can be used as the preferred drug in the clinical treatment program.